Related Experiment Videos
Is primary antiarrhythmic drug therapy for ventricular arrhythmias obsolete?
1Milwaukee Heart Institute, 960 North 12th Street, Milwaukee, Wisconsin 53233, USA.
Insights
Sudden cardiac death (SCD) is a major threat. Implantable cardioverter defibrillators (ICDs) are superior to antiarrhythmic drugs for preventing recurrent life-threatening arrhythmias and saving lives in patients with aborted SCD.
Area of Science:
- Cardiology
- Electrophysiology
- Public Health
Background:
- Sudden cardiac death (SCD) poses a significant public health challenge.
- Patients experiencing aborted SCD are at high risk for recurrent life-threatening ventricular arrhythmias.
- Early antiarrhythmic drug therapies showed limited efficacy and high event rates.
Purpose of the Study:
- To evaluate the effectiveness of implantable cardioverter defibrillators (ICDs) compared to antiarrhythmic drug therapy for secondary prevention of SCD.
- To determine the optimal treatment strategy for patients with a history of aborted SCD and ventricular arrhythmias.
Main Methods:
- The study references findings from major clinical trials, including the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial and the Canadian Implantable Defibrillator Study (CIDS).
- These trials compared the efficacy of ICDs against the best available medical therapy, primarily antiarrhythmic drugs.
Main Results:
- Both the AVID and CIDS trials demonstrated the superiority of ICDs over conventional antiarrhythmic drug therapy.
- ICDs significantly improved survival rates in patients at high risk for recurrent life-threatening arrhythmias.
Conclusions:
- Implantable cardioverter defibrillators (ICDs) represent a superior treatment modality for the secondary prevention of sudden cardiac death compared to antiarrhythmic drugs.
- The findings question the primary role of antiarrhythmic drug therapy in managing patients with aborted SCD and highlight the life-saving benefits of ICDs.
Abstract:
Sudden cardiac death (SCD) remains a major public health threat. Patients with aborted SCD have a high incidence of recurrent life-threatening ventricular arrhythmias. Antiarrhythmic drug approaches dominated early attempts to prevent SCD; however, several trials with sotalol and amiodarone revealed an unacceptably high rate of recurrent arrhythmic events. With the advent of the implantable cardioverter defibrillator (ICD), the primary role of antiarrhythmic drug therapy for the secondary prevention of SCD has been called into question. Two recently completed trials, the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial and the Canadian Implantable Defibrillator Study (CIDS), confirm the superiority of the ICD over the best medical therapy for saving lives.